# What Are Contingent Value Rights? Published: 2026-03-12 Author: Warren Team URL: https://www.heywarren.com/blog/contingent-value-rights --- When Bristol-Myers Squibb acquired Celgene in 2019 for $74 billion, shareholders received not just cash and stock — they also got a small, cryptic instrument called a [contingent value right](/blog/contingent-value-right) that could pay out an additional $9 per share if three drugs hit regulatory milestones. Most retail investors had no idea what to do with it. Some sold immediately for pennies. Others held on through years of uncertainty, watching the CVR trade as low as $0.35 before eventually expiring worthless. The difference in outcome between informed and uninformed investors was stark. Contingent value rights appear more often than most people realize, yet they remain one of the least understood components of merger deals. Many shareholders toss them aside without understanding whether they represent genuine upside or a distraction with little real value. In this guide, you will learn exactly how contingent value rights work, what triggers a payout, how to evaluate whether they are worth holding, and what the historical track record looks like for CVRs across major [acquisitions](/blog/what-is-acquisitions). By the end, you will have the framework to make an informed decision the next time one lands in your brokerage account. --- ## What Are Contingent Value Rights? A contingent value right (CVR) is a contractual promise made by an acquiring company to pay target shareholders an additional sum of money if certain predefined conditions are met within a specified time frame. In plain terms, it is a "we'll pay you more later — if this happens" clause attached to a merger deal. CVRs function as a bridge between a buyer and seller who disagree on a company's future value. The acquiring company wants to pay based on what it knows today. Target shareholders believe the company is worth more if certain events unfold — a drug gets FDA approval, a revenue threshold is crossed, or a lawsuit resolves favorably. The CVR splits the difference. These instruments are most common in pharmaceutical and biotech acquisitions, where the value of a pipeline drug can swing wildly depending on clinical trial outcomes. But they also appear in technology, media, and financial sector deals. ### CVRs vs. Earnouts While CVRs and earnouts both involve contingent payments, they differ in one key way. An earnout typically applies to the management or founders of the target company and incentivizes them to hit performance goals post-acquisition. A CVR is issued directly to shareholders of the target company, often as a tradeable security, with no expectation that recipients remain involved with the business. ### CVRs vs. Warrants A warrant gives the holder the right to buy shares at a set price. A CVR gives the holder the right to receive cash — but only if something specific happens. Warrants have intrinsic value even before an event occurs. CVRs have zero value if the triggering milestone is never reached. --- ## How Contingent Value Rights Work in a Merger When a deal closes, shareholders of the acquired company receive their stated merger consideration — usually a combination of cash and stock. Along with that consideration, each share they hold may entitle them to one CVR, which is then either held or sold separately. ![The five stages a contingent value right passes through from deal announcement to payout or expiry.](data:image/svg+xml,%3Csvg%20xmlns%3D%22http%3A%2F%2Fwww.w3.org%2F2000%2Fsvg%22%20viewBox%3D%220%200%20800%20149%22%20width%3D%22800%22%20height%3D%22149%22%20role%3D%22img%22%3E%3Ctitle%3ETimeline%3C%2Ftitle%3E%3Crect%20width%3D%22100%25%22%20height%3D%22100%25%22%20fill%3D%22%23f8fafc%22%2F%3E%3Cline%20x1%3D%22120%22%20y1%3D%2255%22%20x2%3D%22680%22%20y2%3D%2255%22%20stroke%3D%22%23cbd5e1%22%20stroke-width%3D%223%22%2F%3E%3Ccircle%20cx%3D%22120%22%20cy%3D%2255%22%20r%3D%2224%22%20fill%3D%22white%22%20stroke%3D%22%23cbd5e1%22%20stroke-width%3D%222%22%2F%3E%3Ctext%20x%3D%22120%22%20y%3D%2260%22%20text-anchor%3D%22middle%22%20font-family%3D%22system-ui%2C-apple-system%2Csans-serif%22%20font-size%3D%2215%22%20font-weight%3D%22700%22%20fill%3D%22%230f172a%22%3E1%3C%2Ftext%3E%3Ctext%20x%3D%22120%22%20y%3D%22101%22%20text-anchor%3D%22middle%22%20font-family%3D%22system-ui%2C-apple-system%2Csans-serif%22%20font-size%3D%2212%22%20font-weight%3D%22600%22%20fill%3D%22%230f172a%22%3EDeal%20Announced%3C%2Ftext%3E%3Ctext%20x%3D%22120%22%20y%3D%22119%22%20text-anchor%3D%22middle%22%20font-family%3D%22system-ui%2C-apple-system%2Csans-serif%22%20font-size%3D%2210%22%20fill%3D%22%2364748b%22%3ECVR%20terms%20disclosed%3C%2Ftext%3E%3Ccircle%20cx%3D%22260%22%20cy%3D%2255%22%20r%3D%2224%22%20fill%3D%22white%22%20stroke%3D%22%23cbd5e1%22%20stroke-width%3D%222%22%2F%3E%3Ctext%20x%3D%22260%22%20y%3D%2260%22%20text-anchor%3D%22middle%22%20font-family%3D%22system-ui%2C-apple-system%2Csans-serif%22%20font-size%3D%2215%22%20font-weight%3D%22700%22%20fill%3D%22%230f172a%22%3E2%3C%2Ftext%3E%3Ctext%20x%3D%22260%22%20y%3D%22101%22%20text-anchor%3D%22middle%22%20font-family%3D%22system-ui%2C-apple-system%2Csans-serif%22%20font-size%3D%2212%22%20font-weight%3D%22600%22%20fill%3D%22%230f172a%22%3EShareholders%20Vote%3C%2Ftext%3E%3Ctext%20x%3D%22260%22%20y%3D%22119%22%20text-anchor%3D%22middle%22%20font-family%3D%22system-ui%2C-apple-system%2Csans-serif%22%20font-size%3D%2210%22%20fill%3D%22%2364748b%22%3EProxy%20filed%20with%20SEC%3C%2Ftext%3E%3Ccircle%20cx%3D%22400%22%20cy%3D%2255%22%20r%3D%2224%22%20fill%3D%22white%22%20stroke%3D%22%23cbd5e1%22%20stroke-width%3D%222%22%2F%3E%3Ctext%20x%3D%22400%22%20y%3D%2260%22%20text-anchor%3D%22middle%22%20font-family%3D%22system-ui%2C-apple-system%2Csans-serif%22%20font-size%3D%2215%22%20font-weight%3D%22700%22%20fill%3D%22%230f172a%22%3E3%3C%2Ftext%3E%3Ctext%20x%3D%22400%22%20y%3D%22101%22%20text-anchor%3D%22middle%22%20font-family%3D%22system-ui%2C-apple-system%2Csans-serif%22%20font-size%3D%2212%22%20font-weight%3D%22600%22%20fill%3D%22%230f172a%22%3EDeal%20Closes%3C%2Ftext%3E%3Ctext%20x%3D%22400%22%20y%3D%22119%22%20text-anchor%3D%22middle%22%20font-family%3D%22system-ui%2C-apple-system%2Csans-serif%22%20font-size%3D%2210%22%20fill%3D%22%2364748b%22%3ECVRs%20distributed%3C%2Ftext%3E%3Ccircle%20cx%3D%22540%22%20cy%3D%2255%22%20r%3D%2224%22%20fill%3D%22%232563eb%22%20stroke%3D%22%232563eb%22%20stroke-width%3D%223%22%2F%3E%3Ctext%20x%3D%22540%22%20y%3D%2260%22%20text-anchor%3D%22middle%22%20font-family%3D%22system-ui%2C-apple-system%2Csans-serif%22%20font-size%3D%2215%22%20font-weight%3D%22700%22%20fill%3D%22white%22%3E4%3C%2Ftext%3E%3Ctext%20x%3D%22540%22%20y%3D%22101%22%20text-anchor%3D%22middle%22%20font-family%3D%22system-ui%2C-apple-system%2Csans-serif%22%20font-size%3D%2212%22%20font-weight%3D%22600%22%20fill%3D%22%230f172a%22%3EMilestone%20Period%3C%2Ftext%3E%3Ctext%20x%3D%22540%22%20y%3D%22119%22%20text-anchor%3D%22middle%22%20font-family%3D%22system-ui%2C-apple-system%2Csans-serif%22%20font-size%3D%2210%22%20fill%3D%22%2364748b%22%3EAcquirer%20pursues%20target%3C%2Ftext%3E%3Ccircle%20cx%3D%22680%22%20cy%3D%2255%22%20r%3D%2224%22%20fill%3D%22white%22%20stroke%3D%22%23cbd5e1%22%20stroke-width%3D%222%22%2F%3E%3Ctext%20x%3D%22680%22%20y%3D%2260%22%20text-anchor%3D%22middle%22%20font-family%3D%22system-ui%2C-apple-system%2Csans-serif%22%20font-size%3D%2215%22%20font-weight%3D%22700%22%20fill%3D%22%230f172a%22%3E5%3C%2Ftext%3E%3Ctext%20x%3D%22680%22%20y%3D%22101%22%20text-anchor%3D%22middle%22%20font-family%3D%22system-ui%2C-apple-system%2Csans-serif%22%20font-size%3D%2212%22%20font-weight%3D%22600%22%20fill%3D%22%230f172a%22%3EHit%20or%20Miss%3C%2Ftext%3E%3Ctext%20x%3D%22680%22%20y%3D%22119%22%20text-anchor%3D%22middle%22%20font-family%3D%22system-ui%2C-apple-system%2Csans-serif%22%20font-size%3D%2210%22%20fill%3D%22%2364748b%22%3EPayout%20or%20expire%20worthless%3C%2Ftext%3E%3C%2Fsvg%3E) *The five stages a contingent value right passes through from deal announcement to payout or expiry.* The mechanics follow a straightforward sequence. 1. **The deal is announced** with a CVR as part of the total offer package. The agreement specifies the milestone, the payout amount per CVR, and the expiration date. 2. **Shareholders vote** on the deal. The CVR terms are disclosed in the proxy statement filed with the SEC. 3. **The deal closes** and CVRs are distributed, often at a ratio of one CVR per target share held. 4. **The milestone period begins.** The acquiring company pursues whatever activity triggers the payout — usually a regulatory filing, approval, or revenue target. 5. **The milestone is either hit or missed.** If it is hit within the agreed window, the acquirer pays the CVR holders the specified amount. If time runs out without success, the CVR expires worthless. A CVR agreement is a legal contract and is publicly filed. CVR holders do not typically have enforcement rights themselves — a trustee or representative, named in the agreement, acts on their behalf. ### Are CVRs Tradeable? Some CVRs are listed on stock exchanges and can be bought or sold like any other security. The Bristol-Myers Squibb CVR issued in the Celgene deal, for example, traded on [Nasdaq](https://www.nasdaq.com/) under the ticker "BMYRT." Tradeable CVRs offer liquidity but also introduce market pricing that may differ significantly from the CVR's theoretical probability-weighted value. Non-tradeable CVRs cannot be sold and must be held until resolution. These are more common in smaller deals and create a purely binary outcome for the holder. --- ## Types of Contingent Value Rights Not all CVRs are structured the same way. The triggering milestone determines the risk profile and likely timeline of the instrument. ![The three main milestone categories that determine a CVR's trigger event and risk profile.](data:image/svg+xml,%3Csvg%20xmlns%3D%22http%3A%2F%2Fwww.w3.org%2F2000%2Fsvg%22%20viewBox%3D%220%200%20600%20211%22%20width%3D%22600%22%20height%3D%22211%22%20role%3D%22img%22%3E%3Ctitle%3EHierarchy%3C%2Ftitle%3E%3Crect%20width%3D%22100%25%22%20height%3D%22100%25%22%20fill%3D%22%23f8fafc%22%2F%3E%3Crect%20x%3D%22220%22%20y%3D%2220%22%20width%3D%22160%22%20height%3D%2258%22%20rx%3D%228%22%20fill%3D%22%232563eb%22%2F%3E%3Ctext%20x%3D%22300%22%20y%3D%2254%22%20text-anchor%3D%22middle%22%20font-family%3D%22system-ui%2C-apple-system%2Csans-serif%22%20font-size%3D%2214%22%20font-weight%3D%22700%22%20fill%3D%22white%22%3ECVR%20Types%3C%2Ftext%3E%3Cpath%20d%3D%22M%20300%2078%20L%20300%20105.5%20L%20120%20105.5%20L%20120%20133%22%20stroke%3D%22%23cbd5e1%22%20stroke-width%3D%222%22%20fill%3D%22none%22%2F%3E%3Crect%20x%3D%2240%22%20y%3D%22133%22%20width%3D%22160%22%20height%3D%2258%22%20rx%3D%228%22%20fill%3D%22white%22%20stroke%3D%22%230891b2%22%20stroke-width%3D%222%22%2F%3E%3Ctext%20x%3D%22120%22%20y%3D%22158%22%20text-anchor%3D%22middle%22%20font-family%3D%22system-ui%2C-apple-system%2Csans-serif%22%20font-size%3D%2213%22%20font-weight%3D%22600%22%20fill%3D%22%230f172a%22%3ERegulatory%3C%2Ftext%3E%3Ctext%20x%3D%22120%22%20y%3D%22176%22%20text-anchor%3D%22middle%22%20font-family%3D%22system-ui%2C-apple-system%2Csans-serif%22%20font-size%3D%2210%22%20fill%3D%22%2364748b%22%3EFDA%2Fregulator%20approval%3C%2Ftext%3E%3Cpath%20d%3D%22M%20300%2078%20L%20300%20105.5%20L%20300%20105.5%20L%20300%20133%22%20stroke%3D%22%23cbd5e1%22%20stroke-width%3D%222%22%20fill%3D%22none%22%2F%3E%3Crect%20x%3D%22220%22%20y%3D%22133%22%20width%3D%22160%22%20height%3D%2258%22%20rx%3D%228%22%20fill%3D%22white%22%20stroke%3D%22%230891b2%22%20stroke-width%3D%222%22%2F%3E%3Ctext%20x%3D%22300%22%20y%3D%22158%22%20text-anchor%3D%22middle%22%20font-family%3D%22system-ui%2C-apple-system%2Csans-serif%22%20font-size%3D%2213%22%20font-weight%3D%22600%22%20fill%3D%22%230f172a%22%3ERevenue%3C%2Ftext%3E%3Ctext%20x%3D%22300%22%20y%3D%22176%22%20text-anchor%3D%22middle%22%20font-family%3D%22system-ui%2C-apple-system%2Csans-serif%22%20font-size%3D%2210%22%20fill%3D%22%2364748b%22%3ESales%20threshold%20hit%3C%2Ftext%3E%3Cpath%20d%3D%22M%20300%2078%20L%20300%20105.5%20L%20480%20105.5%20L%20480%20133%22%20stroke%3D%22%23cbd5e1%22%20stroke-width%3D%222%22%20fill%3D%22none%22%2F%3E%3Crect%20x%3D%22400%22%20y%3D%22133%22%20width%3D%22160%22%20height%3D%2258%22%20rx%3D%228%22%20fill%3D%22white%22%20stroke%3D%22%230891b2%22%20stroke-width%3D%222%22%2F%3E%3Ctext%20x%3D%22480%22%20y%3D%22158%22%20text-anchor%3D%22middle%22%20font-family%3D%22system-ui%2C-apple-system%2Csans-serif%22%20font-size%3D%2213%22%20font-weight%3D%22600%22%20fill%3D%22%230f172a%22%3ELitigation%3C%2Ftext%3E%3Ctext%20x%3D%22480%22%20y%3D%22176%22%20text-anchor%3D%22middle%22%20font-family%3D%22system-ui%2C-apple-system%2Csans-serif%22%20font-size%3D%2210%22%20fill%3D%22%2364748b%22%3ELegal%20or%20asset%20resolution%3C%2Ftext%3E%3C%2Fsvg%3E) *The three main milestone categories that determine a CVR's trigger event and risk profile.* ### Regulatory Milestone CVRs These are the most common type, especially in pharmaceutical deals. The payout is tied to a drug or therapy receiving approval from the FDA or a comparable international regulator. The timeline is tied to the regulatory process, which can stretch for years. Sanofi's acquisition of Genzyme in 2011 is a classic example — shareholders received a CVR tied to the MS drug lemtrada reaching specified sales milestones after FDA approval. ### Revenue or Sales Milestone CVRs Here, the trigger is a commercial performance target. If the acquired business hits $500 million in revenue by year three, CVR holders receive their payout. These are common in technology and consumer product acquisitions where the target's growth trajectory is uncertain. The risk is tied to market execution rather than regulatory outcomes. ### Litigation or Asset Resolution CVRs These CVRs pay out when a legal claim is resolved favorably or when a specific asset — a patent, a real estate holding, a subsidiary — is sold above a threshold price. These can have unpredictable timelines because litigation does not follow a preset schedule. --- ## Real-World Examples of CVR Deals Looking at how contingent value rights have played out historically gives investors a grounded sense of the risk involved. **Celgene / Bristol-Myers Squibb (2019):** The CVR offered $9 per share upon FDA approval of three drugs — ozanimod, liso-cel, and ide-cel — by specific deadlines. Only ozanimod received approval on time. The CVR expired worthless in 2021, representing a loss for the many shareholders who held rather than sold at market prices above $1.00. **Sanofi / Genzyme (2011):** Genzyme shareholders received a CVR that would pay up to $14 per share if lemtrada hit sales milestones from 2012 to 2020. The drug received FDA approval in 2014 but never reached commercial sales targets. The CVR paid out a fraction of its maximum value before expiring. **AstraZeneca / Ardea Biosciences (2012):** Ardea shareholders received a CVR tied to the gout drug lesinurad meeting regulatory and sales milestones. The FDA approved lesinurad in 2015, and milestone payments were made to CVR holders — one of the more successful CVR outcomes on record. **Amgen / BioSig Technologies (smaller deal, 2022):** A non-tradeable CVR structured around cardiac mapping device sales thresholds demonstrated the instrument's use outside the biotech drug approval context. The track record is mixed. Pharmaceutical CVRs dependent on FDA approval have a roughly 50-60% failure rate, mirroring the broader clinical trial attrition rate for drugs in late-stage development. --- ## Risks and Rewards of Contingent Value Rights for Shareholders Understanding the risk-reward profile of a CVR requires looking at both sides honestly. ### The Case for Holding a CVR If you receive a CVR with a stated payout of $5 per right, and the market is pricing it at $0.50, you are implicitly being offered 10-to-1 odds on a single event. If you have reason to believe the probability of that event is greater than 10%, holding — or even buying more on the open market — can be mathematically attractive. Informed investors who closely follow a drug's clinical data, competitive landscape, and regulatory pathway may have a genuine informational edge. For sophisticated biotech investors, traded CVRs can represent mispriced probability instruments. ### The Case for Selling a CVR For most retail investors, holding a CVR means accepting concentrated binary risk in a single outcome they likely cannot evaluate. The payout may be small in absolute terms. The time horizon can stretch three to five years. And the acquirer — who now controls the asset — has every incentive to manage the process in ways that minimize its own payout obligation. CVR agreements sometimes contain language that critics argue gives the acquirer discretion in how aggressively to pursue the milestone. A company that paid $74 billion for a target has some incentive to pursue FDA approvals vigorously. But the priority may not always align with CVR holders' interests. ### Tax Treatment of CVRs In the United States, the [IRS](https://www.irs.gov/) does not have a definitive, consistent ruling on how CVRs are taxed at issuance. Many tax advisors treat them as having zero fair market value at receipt, meaning no taxable event occurs until the CVR pays out or is sold. At that point, proceeds may be treated as ordinary income or capital gain depending on the structure. Always consult a tax professional for guidance specific to your situation. --- ## How to Evaluate Contingent Value Rights Before Deciding When a CVR lands in your account, a structured evaluation process will help you decide whether to hold, sell, or in rare cases, buy more on the open market. **Step 1: Read the CVR agreement.** The proxy statement and Form 8-K filed with the SEC will include the complete CVR agreement. Look for: the exact milestone definition, the deadline, who acts as trustee, and what enforcement rights holders have. **Step 2: Assess the milestone probability.** For drug approval CVRs, review the phase 3 clinical data, the competitive landscape in the target indication, and the FDA's recent decisions on similar drugs. Resources like Evaluate Pharma and ClinicalTrials.gov provide publicly available data. **Step 3: Check the current market price.** If the CVR trades publicly, compare the market price to a probability-weighted expected value calculation. If the milestone pays $5, and you estimate a 30% probability of success, the expected value is $1.50. If the CVR trades at $0.60, it may be underpriced by the market. **Step 4: Consider the timeline.** A CVR with a three-year window and an uncertain outcome requires capital to be tied up. Compare that [opportunity cost](/blog/formula-of-opportunity-cost) to other uses of your money. **Step 5: Evaluate acquirer incentives.** Research whether the acquiring company has made public statements about the milestone product. If the CEO has been enthusiastic about commercializing the asset, that is a positive signal. --- ## Related Reading **More from Warren**: - [What Is EBITDA and Why Does It Matter?](/blog/how-is-ebitda-calculated) - [Qualified Institutional Buyers (QIBs): Definition and Why They Matter in Capital Markets](/blog/qualified-institutional-buyers) - [What Is a Monopolist? A Clear Definition](/blog/monopolist-example) ## Authoritative Sources For deeper background and primary-source data on this topic, the following authoritative sources are useful starting points: - [SEC](https://www.sec.gov/) - [Federal Reserve](https://www.federalreserve.gov/) - [Consumer Financial Protection Bureau](https://www.consumerfinance.gov/) - [U.S. Department of the Treasury](https://home.treasury.gov/) ## Conclusion Contingent value rights are one of the most misunderstood instruments in mergers and acquisitions — simultaneously a deal sweetener, a risk transfer mechanism, and a source of genuine confusion for everyday investors. Here are the key takeaways from this guide: - A contingent value right pays out only if a specific milestone — typically FDA approval, a sales target, or a legal outcome — is met within a defined window. - CVRs are most common in pharmaceutical and biotech deals, where pipeline drug uncertainty makes it hard for buyers and sellers to agree on price. - The historical track record is mixed. High-profile CVRs like the Celgene deal have expired worthless, while others like Ardea Biosciences paid out successfully. - Tradeable CVRs offer liquidity and can sometimes be mispriced by the market, creating opportunities for investors with genuine analytical edge. - Before deciding to hold or sell, read the CVR agreement, assess milestone probability, and compare the market price to your probability-weighted estimate. Contingent value rights reward informed investors and penalize passive ones. The outcome is rarely random — it tracks the underlying science, commercial execution, or legal merits of the triggering event. Ready to put this knowledge to work? Try Warren, your AI financial advisor — get personalized, conflict-free guidance at heywarren.com